A different treatment experience backed by a robust body of evidence
years of postmarketing experience1
years of total clinical use2*
clinical trials across indications1,2†
patient-years of worldwide cumulative exposure2‡
CIMZIA is the only Fc-free anti-TNF3-7
CIMZIA does not contain an Fc portion, which is present in a fully formed antibody.
A monovalent TNF inhibitor monoclonal antibody fragment, CIMZIA neutralizes TNF-alpha at low concentrations with a high affinity.1
PEGylation changes the physical and chemical properties of the biochemical molecule.8
- Increases bioavailability of CIMZIA9,10
- Extends half-life of the antigen-binding fragment1,5
- Increases drug stability and retention time, thereby allowing a reduced dosing frequency5,8
Clinical relevance of in vitro and in vivo data is unknown.